Method for reducing pain with ziconotide and baclofen
View Patent ↗The present invention is direct to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyil, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the ω-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound. A preferred route of administration is intrathecal administration, particularly continuous intrathecal infusion. The present invention is also directed to a pharmaceutical formulation comprising an omega conopeptide, preferably ziconotide, an antioxidant, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil.
1. A method for reducing pain in a patient, comprising:
administering to a patient in need thereof 0.6-4.8 μg/day of ziconotide and 22-800 μg/day of baclofen, wherein said administering is continuous intrathecal infusion.
2. The method according to claim 1 , wherein said ziconotide is in a solution containing an antioxidant.
3. The method according to claim 2 , wherein said antioxidant is methionine.
4. The method according to claim 2 , wherein said solution has pH between 4 to 4.5.
5. The method according to claim 2 , wherein said baclofen is administered at a constant dosage and said ziconotide is administrated at an increasing dosage each week.
6. The method according to claim 2 , wherein said patient is treated for 7 weeks.
7. The method according to claim 2 , wherein said administration is performed using a drug dispensing implantable pump.
8. The method according to claim 7 , wherein the flow rate of said pump is at least 288 μL/day.
9. A method for treating spasticity in a patient, comprising:
administering to a patient in need thereof 0.6-4.8 μg/day of ziconotide and 22-800 μg/day of baclofen, wherein said administering is continuous intrathecal infusion.
10. The method according to claim 9 , wherein said ziconotide is in a solution containing an antioxidant.
11. The method according to claim 10 , wherein said antioxidant is methionine.
12. The method according to claim 10 , wherein said solution has pH between 4 to 4.5.
13. The method according to claim 10 , wherein said baclofen is administered at a constant dosage and said ziconotide is administrated at an increasing dosage each week.
14. The method according to claim 10 , wherein said patient is treated for 7 weeks.
15. The method according to claim 10 , wherein said administration is performed using a drug dispensing implantable pump.
16. The method according to claim 15 , wherein the flow rate of said pump is at least 288 μL/day.